(Q44202471)

30 November 2017

title

Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics (English)

1 reference

30 November 2017

1 reference

1 reference

Donna J Belle

1

1 reference

30 November 2017

C Steven Ernest

2

1 reference

30 November 2017

John-Michael Sauer

3

1 reference

30 November 2017

Brian P Smith

4

1 reference

30 November 2017

Holly R Thomasson

5

1 reference

30 November 2017

Jennifer W Witcher

6

1 reference

30 November 2017

publication date

1 November 2002

1 reference

The Journal of Clinical Pharmacology

30 November 2017

published in

1 reference

30 November 2017

volume

42

1 reference

30 November 2017

issue

11

1 reference

30 November 2017

page(s)

1219-1227

1 reference

Localization of rat brain binding sites for [3H]tomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491307

Identification of the human cytochromes P450 responsible for atomoxetine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491307

Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491307

The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491307

Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491307

Psychiatric comorbidity in patients with attention deficit disorder: a controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491307

Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491307

Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491307

Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491307

Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491307

Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491307

Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491307

The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491307

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491307

Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491307

The relationship between paroxetine and the sparteine oxidation polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491307

Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491307

Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491307

Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491307

Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491307

The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491307

Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491307

Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491307

Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002762491307

10.1177/009127002762491307

21 January 2018

Identifiers

DOI

1 reference

30 November 2017

1 reference